[go: up one dir, main page]

MX2021003002A - Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo. - Google Patents

Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo.

Info

Publication number
MX2021003002A
MX2021003002A MX2021003002A MX2021003002A MX2021003002A MX 2021003002 A MX2021003002 A MX 2021003002A MX 2021003002 A MX2021003002 A MX 2021003002A MX 2021003002 A MX2021003002 A MX 2021003002A MX 2021003002 A MX2021003002 A MX 2021003002A
Authority
MX
Mexico
Prior art keywords
composition
fibrotic diseases
active ingredient
treating fibrotic
thioacetamide compound
Prior art date
Application number
MX2021003002A
Other languages
English (en)
Inventor
Suk Hyo Suh
Seong Jin Kim
Original Assignee
Cellionbiomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellionbiomed Inc filed Critical Cellionbiomed Inc
Publication of MX2021003002A publication Critical patent/MX2021003002A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición para el tratamiento de enfermedades fibróticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo, y más específicamente a una composición para el tratamiento de enfermedades fibróticas, que suprime la expresión de la proteína del canal KCa2.3 en una membrana celular y tiene excelentes efectos de tratamiento particularmente sobre la fibrosis hepática y la fibrosis pulmonar.
MX2021003002A 2018-09-14 2019-09-11 Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo. MX2021003002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180110442A KR102126389B1 (ko) 2018-09-14 2018-09-14 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물
PCT/KR2019/011834 WO2020055166A1 (ko) 2018-09-14 2019-09-11 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 섬유화 질환의 치료용 조성물

Publications (1)

Publication Number Publication Date
MX2021003002A true MX2021003002A (es) 2021-05-27

Family

ID=69777998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003002A MX2021003002A (es) 2018-09-14 2019-09-11 Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo.

Country Status (11)

Country Link
US (1) US20210260018A1 (es)
EP (1) EP3851099B1 (es)
JP (1) JP7184241B2 (es)
KR (1) KR102126389B1 (es)
CN (1) CN113038942A (es)
AU (1) AU2019338896B2 (es)
BR (1) BR112021004766A2 (es)
CA (1) CA3112695C (es)
MX (1) MX2021003002A (es)
RU (1) RU2769364C1 (es)
WO (1) WO2020055166A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102277739B1 (ko) * 2019-12-11 2021-07-15 셀라이온바이오메드 주식회사 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 섬유화 질환의 치료용 조성물
KR102821592B1 (ko) 2021-08-02 2025-06-17 셀라이온바이오메드 주식회사 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 비후성 반흔 및 켈로이드 치료용 조성물
WO2023014003A1 (ko) 2021-08-02 2023-02-09 셀라이온바이오메드 주식회사 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 비후성 반흔 및 켈로이드 치료용 조성물
CN113750089B (zh) * 2021-10-13 2023-09-19 南方医科大学南方医院 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗慢性肝病的药物中的用途
KR20240158008A (ko) 2023-04-26 2024-11-04 셀라이온바이오메드 주식회사 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 알러지 및 자가면역질환 치료용 조성물
CN116492469A (zh) * 2023-05-22 2023-07-28 遵义医科大学附属医院 一种通道阻滞剂在制备治疗和/或预防肝纤维疾病药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520812A (en) 1975-10-02 1978-08-09 Lafon Labor Benzhydrylsulphinyl derivatives
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2528038B2 (fr) * 1982-06-04 1985-08-09 Lafon Labor Derives de benzhydrylsulfinylacetamide et leur utilisation en therapeutique
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2606015B1 (fr) * 1986-08-13 1989-05-19 Lafon Labor Derives du benzhydrylthiomethane, leurs procedes de preparation et leurs applications en therapeutique
FR2708201B1 (fr) * 1993-06-30 1995-10-20 Lafon Labor Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
CA2280309C (en) 1999-08-13 2007-05-08 William Norton Milgram Use of adrafinil to treat behavioral problems in aged canines
US6870361B2 (en) 2002-12-21 2005-03-22 Agilent Technologies, Inc. System with nano-scale conductor and nano-opening
KR101121671B1 (ko) 2003-08-12 2012-03-14 미쓰이 가가쿠 가부시키가이샤 광경화형 수지 조성물 및 그것을 이용한 플랫 패널디스플레이용 실링제
CA2556106A1 (en) * 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
FR2970711B1 (fr) * 2011-01-20 2016-03-04 Hopitaux Paris Assist Publique La lauflumide et ses enantiomeres, preparation et utilisations therapeutiques
KR101414831B1 (ko) * 2011-10-25 2014-07-04 이화여자대학교 산학협력단 모다피닐 또는 이의 유도체를 포함하는 ＫＣａ3.1 채널 매개 질환 치료용 조성물
KR101345860B1 (ko) 2011-10-25 2013-12-30 이화여자대학교 산학협력단 모다피닐 또는 이의 유도체를 포함하는 혈관질환 치료용 조성물
KR101402969B1 (ko) * 2012-01-04 2014-06-03 이화여자대학교 산학협력단 신규한 모다피닐 유도체 및 이를 포함하는 염증 예방 또는 치료용 약학적 조성물
CA2903746C (en) * 2013-03-08 2022-08-23 Amy Hauck Newman Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
ES2566430B1 (es) * 2014-09-12 2017-01-26 Instituto Aragones De Ciencias De La Salud Esteres de di-benzoato y su uso terapéutico como moduladores negativos de canales de potasio KCa2/3

Also Published As

Publication number Publication date
CN113038942A (zh) 2021-06-25
KR20200031436A (ko) 2020-03-24
RU2769364C1 (ru) 2022-03-30
CA3112695A1 (en) 2020-03-19
US20210260018A1 (en) 2021-08-26
AU2019338896B2 (en) 2022-10-20
BR112021004766A2 (pt) 2021-08-31
EP3851099A4 (en) 2023-03-08
AU2019338896A1 (en) 2021-04-08
KR102126389B1 (ko) 2020-06-25
JP2021536459A (ja) 2021-12-27
EP3851099B1 (en) 2025-12-31
EP3851099A1 (en) 2021-07-21
CA3112695C (en) 2023-10-10
WO2020055166A1 (ko) 2020-03-19
JP7184241B2 (ja) 2022-12-06

Similar Documents

Publication Publication Date Title
MX2021003002A (es) Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo.
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CO2021012176A2 (es) Preparaciones de membrana bacteriana
UY38160A (es) Partículas implantables y métodos relacionados
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CO2022010305A2 (es) Método y aplicación de preparación de compuesto como agente de degradación de proteínas
MX386927B (es) Composicion y metodo para el crecimiento del cabello.
NI201400841A (es) Composición veterinaria blanda masticable para tratar y/o prevenir una infección o infección de parásitos en un animal
NI201700135A (es) Derivados de ciclohexano sustituido con amido
UY37480A (es) Nuevos derivados de quinolina
CL2018001744A1 (es) Compuestos depsipeptídicos como anthelmínticos
UY37831A (es) Nuevos derivados de quinolina
MX2016009449A (es) Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb).
WO2020171727A3 (en) Mucoadhesive compositions and uses thereof
CL2020002252A1 (es) Formulación oftálmica.
CO2020013876A2 (es) Nuevos derivados de quinolina
PE20211755A1 (es) Moduladores de la expresion de hsd17b13
UY36920A (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral
CL2011000583A1 (es) Composicion plaguicida que comprende un derivado del ácido alfa-alcoxifenil-acetico y un compuesto neonicotenoide.
EA202092748A1 (ru) Модуляторы экспрессии apol1
MX2021007201A (es) Producto estable con esta?o para el cuidado oral.
MX389692B (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc.
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.